Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Sarcopenia Drugs and Companies Pipeline Review H2 2016

Friday, October 21, 2016 4:07
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

 

Get Sample Report @ https://www.wiseguyreports.com/reports/619274-sarcopenia-pipeline-review-h2-2016

 

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcopenia

- The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects

- The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Sarcopenia

 

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sarcopenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Sarcopenia Overview 7

Therapeutics Development 8

Pipeline Products for Sarcopenia – Overview 8

Pipeline Products for Sarcopenia – Comparative Analysis 9

Sarcopenia – Therapeutics under Development by Companies 10

Sarcopenia – Therapeutics under Investigation by Universities/Institutes 11

Sarcopenia – Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Sarcopenia – Products under Development by Companies 14

Sarcopenia – Products under Investigation by Universities/Institutes 15

Sarcopenia – Companies Involved in Therapeutics Development 16

Atara Biotherapeutics, Inc. 16

Biophytis SAS 17

GlaxoSmithKline Plc 18

MYOS RENS Technology Inc. 19

Neurotune AG 20

Novartis AG 21

PsiOxus Therapeutics Limited 22

Regeneron Pharmaceuticals, Inc. 23

Sumitomo Dainippon Pharma Co., Ltd. 24

Sarcopenia – Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

ARM-210 – Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

ATA-842 – Drug Profile 36

Product Description 36

Mechanism Of Action 36

 

Access Report @ https://www.wiseguyreports.com/reports/619274-sarcopenia-pipeline-review-h2-2016        

 

Contact Info:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)                                                   

 

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.